Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Cardinal Health, Inc. (CAH) — XLV Health Care · S&P 500 Profile |康德樂介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Cardinal Health, Inc. (CAH) — Business, History & S&P 500 Profile |康德樂介紹

Cardinal Health company profile · pharmaceutical & medical products distribution · history · financial snapshot · S&P 500 rank #212 · 康德樂公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 30, 2026 (frozen benchmark)
Financials: FY2025 (ended June 30, 2025)
MARKET CAP
$58.00B
Oct 30, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.08%
Rank #212 · Oct 30, 2026 (Slickcharts)
FY2025 REVENUE
$222.58B
−1.9% YoY
FY2025 NET INCOME
$1.56B
FY2025 net income

SNAPSHOT

TickerCAH (NYSE)
CompanyCardinal Health, Inc.
GICS sector / industryHealth Care (XLV) / Health Care Providers & Services
S&P 500 rank (by weight)#212 · 0.08% (Oct 30, 2026)
Sector rank (by market cap)#26 in Health Care (Oct 30, 2026)
Share price (frozen benchmark)$250.48 (Oct 30, 2026)
HeadquartersDublin, Ohio
Founded1971 (as Cardinal Foods)
CEOJason M. Hollar (CEO)
Employeesabout 48,000 (2025 profile)
Market cap$58.00B (Oct 30, 2026)

WHAT IT DOES

Cardinal Health is one of the three largest pharmaceutical distributors in the United States, moving branded and generic drugs from manufacturers to pharmacies, hospitals and clinics, and it also manufactures and distributes medical and surgical products. Its scale lets it negotiate purchasing terms and run a national logistics network that delivers daily.

The model is high-volume, low-margin distribution: revenue is enormous, margins are thin, and profit comes from purchasing scale, logistics efficiency and fee-based services. FY2025 revenue was $222.58B, down 1.9% from $226.83B, and net income was $1.56B.

Cardinal's fiscal year ends June 30, so its FY2025 is the year ended June 30, 2025 — not the calendar year. The following fiscal year, FY2026, reported higher revenue of $254.25B; that is a different fiscal year and is not used in this profile.

BUSINESS SEGMENTS — FY2025 NET SALES

SegmentRevenueShareYoY
Pharmaceutical segment———
Medical segment———
Segment revenue split not stated in the sources used; units are listed qualitatively, with revenue, share and YoY shown as —. Do not read a split from this table.

HISTORY

YearMilestone
1971Founded in Columbus, Ohio, as Cardinal Foods, a food distributor
1979Enters pharmaceutical distribution
1983Initial public offering
1990sGrows by acquisition into one of the largest United States drug distributors
2025FY2025 revenue reaches $222.58B for the year ended June 30, 2025

COMPETITIVE POSITION

  • Purchasing scale — one of three national distributors, with leverage over suppliers.
  • Daily logistics — a national network delivers to pharmacies and hospitals every day.
  • Medical products — owned medical and surgical products add margin above pure distribution.
  • Competition — AmerisourceBergen (Cencora) and McKesson contest the same customers.
  • Thin margins — distribution margins are fractions of a percent, so execution errors cost dearly.

FINANCIAL SNAPSHOT — FY2025

Total revenue$222.58B (−1.9% YoY)
Prior-year revenue$226.83B
Net income$1.56B
Source: Cardinal Health FY2025 results (fiscal year ended June 30, 2025). Fiscal year ends June 30: FY2025 is the year ended June 30, 2025. FY2026 figures (revenue $254.25B, net income $1.71B) belong to the next fiscal year and are not used here. Employee figure is a 2025 profile figure.

KEY RISKS

  • Customer concentration — a few large pharmacy chains account for much of revenue.
  • Thin margins — small pricing or fee changes move profit sharply.
  • Opioid litigation legacy — settlement costs and scrutiny continue from past opioid distribution.
  • Generic deflation — falling generic prices pressure distribution revenue.
  • Regulatory scrutiny — drug pricing and supply-chain rules affect distributor economics.

WHY IT MATTERS FOR THE S&P 500

Cardinal is the S&P 500's drug distributor: at a 0.08% index weight and #26 in Health Care by market cap, it is the index's main exposure to pharmaceutical distribution economics.

Its volumes are a standing read on United States drug demand — prescription flows through its warehouses before they show up in pharmacy sales.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 30, 2026 close)
FinancialsCardinal Health FY2025 Form 10-K results (fiscal year ended June 30, 2025), company profile sources
Sector classificationGICS (Health Care Providers & Services) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

CAH

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼CAH(NYSE)
公司Cardinal Health, Inc.
GICS 板塊/行業醫療保健(XLV)/醫療保健供應商與服務
標普500排名(按權重)#212 · 0.08%(2026 年 10 月 30 日)
板塊內排名(按市值)醫療保健第 #26(2026 年 10 月 30 日)
股價(凍結基準)$250.48(2026 年 10 月 30 日)
總部美國俄亥俄州都柏林
成立1971 年(原名 Cardinal Foods)
行政總裁Jason M. Hollar(行政總裁)
員工約 48,000(2025 年簡介)
市值$58.00B(2026 年 10 月 30 日)

業務概覽

康德樂是美國三大藥品分銷商之一,將品牌藥與仿製藥由廠商運往藥房、醫院與診所,並製造及分銷醫療與外科產品。其規模令其可談判採購條件,並經營每日送貨的全國物流網絡。

其模式為高銷量、低利潤分銷:收入龐大、利潤率薄,利潤來自採購規模、物流效率與收費服務。FY2025 收入為 $222.58B,同比下跌 1.9%(FY2024 為 $226.83B),淨利潤為 $1.56B。

康德樂財政年度截至 6 月 30 日,故其 FY2025 為截至 2025 年 6 月 30 日的年度,並非曆年。其後一財政年度 FY2026 收入較高,為 $254.25B;那是另一財政年度,本簡介不予採用。

業務板塊 — FY2025

板塊收入佔比同比
藥品板塊———
醫療板塊———
板塊收入拆分未見於所用來源;本表只作定性列示,收入、佔比與同比均記為 —,請勿據此推斷拆分。

歷史沿革

年份里程碑
1971在俄亥俄州哥倫布創立,原名 Cardinal Foods,為食品分銷商
1979進入藥品分銷
1983首次公開招股
1990 年代透過收購成長為美國最大的藥品分銷商之一
2025FY2025 收入達 $222.58B,財政年度截至 2025 年 6 月 30 日

競爭地位

  • 採購規模——全國三大分銷商之一,對供應商有議價能力。
  • 每日物流——全國網絡每日向藥房與醫院送貨。
  • 醫療產品——自有醫療與外科產品的利潤率高於純分銷。
  • 競爭——AmerisourceBergen(Cencora)與 McKesson 爭奪同一批客戶。
  • 利潤薄——分銷利潤率不足百分之一,執行失誤代價高昂。

財務快照 — FY2025

總收入$222.58B(同比 −1.9%)
上年度收入$226.83B
淨利潤$1.56B
來源:康德樂 FY2025 業績(財政年度截至 2025 年 6 月 30 日)。財政年度截至 6 月 30 日:FY2025 為截至 2025 年 6 月 30 日的年度。FY2026 數字(收入 $254.25B、淨利潤 $1.71B)屬下一財政年度,本簡介不予採用。員工數字為 2025 年簡介數字。

主要風險

  • 客戶集中——少數大型連鎖藥房佔收入的大部分。
  • 利潤薄——定價或收費微變即可大幅影響利潤。
  • 阿片類訴訟遺留——以往阿片類藥物分銷的和解成本與審查持續。
  • 仿製藥通縮——仿製藥價格下跌壓縮分銷收入。
  • 監管審查——藥價與供應鏈規則影響分銷商經濟效益。

對標普500的重要性

康德樂是標普500的藥品分銷商:指數權重 0.08%、醫療保健板塊市值第 #26,是指數對藥品分銷經濟的主要敞口。

其銷量是美國藥品需求的常設讀數——處方藥流經其倉庫後,方體現於藥房銷售。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 30 日收盤)
財務康德樂 FY2025 Form 10-K 業績(財政年度截至 2025 年 6 月 30 日)、公司簡介來源
板塊分類GICS(醫療保健供應商與服務),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

CAH

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · CAH
Data as of Oct 30, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Cencora, Inc. (COR) — XLV Health Care · S&P 500 Profile |Cencora 介紹Next · TransDigm Group Incorporated (TDG) — XLI Industrials · S&P 500 Profile |TransDigm 集團介紹

Entered 2026-10-31 11:33 · updated 2026-11-14 23:07 · rev 6